Clinical Trials

86 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05286060 2026-02-09

GENUINE

56 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05980000 2026-02-06

Rambro2

37 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

45 enrolled

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05814666 2026-01-30

PEMDA-HN

69 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck

NCT02769520 2026-01-28

Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck

27 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

78 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT04858269 2026-01-28

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

36 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT04862455 2026-01-23

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

14 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03942653 2025-12-31

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

20 enrolled

Salivary Gland Neoplasms

NCT04227509 2025-12-31

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT05119296 2025-12-22

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

12 enrolled

Thyroid Neoplasms

NCT05420948 2025-12-22

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

30 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04414540 2025-12-19

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

20 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04811027 2025-12-11

TACTI-003

171 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT05433116 2025-12-02

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

50 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04454489 2025-11-19

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

21 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT04854499 2025-11-19

ELEVATE HNSCC

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT04225117 2025-11-03

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT02882282 2025-10-23

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

15 enrolled 8 charts

Mouth Neoplasms

NCT03049618 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

42 enrolled 40 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04643379 2025-10-22

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

54 enrolled

Oropharyngeal Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT06161545 2025-10-20

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

40 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04209660 2025-10-07

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

64 enrolled

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05996523 2025-10-03

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

16 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT02841748 2025-10-01

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

100 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04260126 2025-10-01

VERSATILE002

95 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05305131 2025-09-23

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

50 enrolled

Nasopharyngeal Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158